齐墩果酸四唑衍生物及其制备方法和用途与流程

文档序号:11686158阅读:352来源:国知局

本发明涉及医药技术领域,具体的说,是齐墩果酸衍生物及其制备方法和用途。



背景技术:

癌症严重威胁人类的生命和健康,癌症死亡率高居我国疾病死亡率的第二位。因此,研究开发新结构类型抗肿瘤化合物,具有重要的理论意义。

齐墩果酸,一种齐墩果烷型五环三萜类化合物,广泛存在于自然界中。齐墩果酸具有保肝、抗癌、抗炎、抗菌、抗糖尿病和抗hiv等药理作用和生物活性。近年来,发现齐墩果酸衍生物对多种肿瘤细胞具有较好的抑制作用。

四氮唑类杂环化合物是一类重要五元芳杂环化合物,在生物、医药、农药等领域的应用非常广泛,在新药研发方面有广泛的应用前景。



技术实现要素:

为解决现有技术中存在的问题,本发明的目的在于,提供一种齐墩果酸四唑衍生物。

本发明的另一目的在于,还提供一种齐墩果酸四唑衍生物的制备方法,以进一步探索、丰富该类化合物抗肿瘤活性的构效关系。

本发明的目的还在于,还提供一种齐墩果酸四唑衍生物的用途,本发明提供的齐墩果酸四唑衍生物能够抑制肿瘤细胞的生长,具有良好的抗肿瘤活性。

本发明所需要解决的技术问题,通过以下技术方案来实现:

作为本发明的第一方面,一种齐墩果酸四唑衍生物,所述齐墩果酸四唑衍生物的结构式如下:

其中:

r选自4-氟苄基,3-氟苄基,2-氟苄基,4-氯苄基,2-氯苄基,3-溴苄基,2-溴苄基,2-硝基苄基,2-氰基苄基,苄基,2-甲基苄基中的任意一种。

作为本发明的第二方面,一种齐墩果酸四唑衍生物的制备方法,合成步骤如下:

(1)将齐墩果酸溶于n,n-二甲基甲酰胺(dmf)中,加入氯乙腈和碳酸钾反应,得到中间体齐墩果烷-12-烯-28酸乙腈酯(1);

(2)将齐墩果烷-12-烯-28酸乙腈酯(1)作为反应物,溶于异丙醇水溶液中(异丙醇/水=3:1,v/v),搅拌下,加入叠氮化钠和氯化锌,回流反应8h,得齐墩果酸2h-四唑-5-甲酯(2)和齐墩果酸1h-四唑-5-甲酯(3)的混和物;

(3)将齐墩果酸1h-四唑-5-甲酯(3)和齐墩果酸2h-四唑-5-甲酯(2)的混和物作为反应物与取代溴苄反应,得到齐墩果酸四唑衍生物。

齐墩果酸四唑衍生物为:齐墩果酸2-取代苄酯-四唑-5-甲酯(2a~2k)和齐墩果酸1-取代苄酯-四唑-5-甲酯(3a~3k),其中,(2a~2k)为齐墩果酸2h四唑衍生物,(3a~3k)为齐墩果酸1h四唑衍生物,结构式分别如下表所示:

2a为:

2b为:

2c为:

2d为:

2e为:

2f为:

2g为:

2h为:

2i为:

2j为:

2k为:

3a为:

3b为:

3c为:

3d为:

3e为:

3f为:

3g为:

3h为:

3i为:

3j为:

3k为:

所述的齐墩果酸四唑衍生物的制备方法,反应路线如下:

作为本发明的第三方面,在抗肿瘤方面的应用。

进一步,所述应用是在制备具有抗肿瘤药物中的应用。

本发明的有益效果:

本发明制备的齐墩果酸四唑衍生物通过药理实验,表明该类化合物相比齐墩果酸具有更优的抗肿瘤活性,本发明的研究结果为该类抗肿瘤化合物的深入研究奠定较好的基础。

具体实施方式

以下结合具体实施例,对本发明作进一步说明。应理解,以下实施例仅用于说明本发明而非用于限定本发明的范围。

下列实施例中未注明具体条件的实验方法,通常按照常规条件,或厂商提供的条件进行。

实施例1:制备齐墩果酸四唑衍生物

(1)制备齐墩果烷-12-烯-28酸乙腈酯(1)

于100ml反应瓶中,依次加入齐墩果酸(5g,11mmol)、50mldmf、氯乙腈(1.05ml,16.5mmol)和k2co3(2.2g,16.5mmol),室温搅拌反应4h。将溶液倾入碎冰中,抽滤,干燥。柱层析分离得白色粉末5g,收率92.0%。

(2)制备中间体齐墩果酸2h-四唑-5-甲酯(2)和齐墩果酸1h-四唑-5-甲酯的混和物(3)

于250ml反应瓶中,加入齐墩果烷-12-烯-28酸乙腈酯(1)(10g,20.2mmol)、90ml异丙醇和30ml水、叠氮钠(4g,60.6mmol)和zncl2(5g,1.821mmol),回流反应8h。将溶液倾入碎冰中,抽滤,干燥。柱层析分离,得白色粉末9.36g,收率86.1%。

(3)制备齐墩果酸-2-对氟苄基四唑-5-甲酯(2a)和齐墩果酸1-对氟苄基四唑-5-甲酯(3a)

于50ml反应瓶中,加入齐墩果酸1h-四唑-5-甲酯和齐墩果酸2h-四唑-5-甲酯的混和物(0.5g,9.3mmol)、5mldmf、对氟苄溴(0.26g,14.0mmol)、k2co3(1.92g,13.95mmol),反应4h,将溶液倾入碎冰中,抽滤,干燥。经硅胶柱层析分离得齐墩果酸2-对氟苄基四唑-5-甲酯(2a)0.28g,齐墩果酸1-对氟苄基四唑-5-甲酯(3a)0.24g,收率分别为44.7%和38.3%。熔点分别为84.5~87.5℃和174.8~177.4℃。

本发明的实施不限于以上实施例,其余化合物制备时,采用相应r取代的化合物作为原料,方法同上。

实施例中所用试剂均为市售分析纯。

部分目标物的外观、总收率、熔点和1hnmr13cnmr和hrms数据如下。

2a:白色粉末,总收率35.4%,mp:84.5~87.5℃;1hnmr(400mhz,cdcl3):δ7.38~7.31(m,1h),7.16~7.13(d,j=8.0hz,1h),7.08~7.03(m,2h),5.74(s,2h),5.35~5.18(m,3h),,2.83~2.79(dd,j=12.0,4.0hz,1h),2.00~1.92(dt,j=16.0,4.0hz,1h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.89(s,3h),0.88(s,3h),0.87(s,3h),0.77(s,3h),0.63(s,3h);hrms:calcdforc39h54fn4o2[m-oh]+629.42034,found629.42253.

2b:白色粉末,总收率33.5%,mp:87.4~89.2℃;1hnmr(400mhz,cdcl3):δ7.40~7.36(dd,j=8.0,4.0hz,2h),7.08~7.04(t,j=8.0hz,2h),5.71(s,2h),5.34~5.24(m,3h),3.22~3.18(dd,j=8.0,4.0hz,1h),2.86~2.81(dd,j=12.0,4.0hz,1h),2.00~1.92(dt,j=16.0,4.0hz,1h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.89(s,3h),0.88(s,3h),0.87(s,3h),0.77(s,3h),0.63(s,3h);hrms:calcdforc39h55fn4o3[m-oh]+629.42056,found629.42253.

2c:白色粉末,总收率33.3%,mp:66.2~70.4℃;hrms:calcdforc39h55fn4o3[m-oh]+629.42018,found629.42253.

2d:白色粉末,总收率40.9%,mp:67.0~70.0℃;1hnmr(400mhz,cdcl3):δ7.36~7.30(dd,j=12.0,8.0hz,4h),5.70(s,1h),5.34~5.22(m,3h),3.22~3.18(dd,j=8.0,4.0hz,1h),2.83~2.79(dd,j=12.0,4.0hz,1h),2.02~1.94(dt,j=16.0,4.0hz,2h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.89(s,3h),0.88(s,3h),0.87(s,3h),0.77(s,3h),0.61(s,3h);hrms:calcdforc39h54o2n4cl[m-oh]+645.39061,found645.39298.

2e:白色粉末,总收率37.5%,mp:77.3~79.0℃;1hnmr(400mhz,cdcl3):δ7.44~7.42(dd,j=8.0,1.2hz,1h),7.73~7.30(dt,j=7.2,1.6hz,1h),7.28~7.24(m,1h),7.18~7.16(dd,j=8.0,1.6hz,1h),5.70(s,2h),5.27~5.22(m,3h),3.22~3.18(dd,j=8.0,4.0hz,1h),2.83~2.79(dd,j=12.0,4.0hz,1h),2.02~1.94(dt,j=16.0,4.0hz,2h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.90(s,3h),0.89(s,3h),0.87(s,3h),0.77(s,3h),0.48(s,3h);hrms:calcdforc39h54o2n4cl[m-oh]+645.39072,found645.39298.

2f:白色粉末,总收率35.6%,mp:71.6~74.2℃;1hnmr(400mhz,cdcl3):δ7.55~7.47(m,2h),7.32~7.22(m,2h),5.90(s,2h),5.37~5.22(m,3h),2.83~2.79(dd,j=12.0,4.0hz,1h),2.02~1.94(dt,j=16.0,4.0hz,2h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.90(s,3h),0.89(s,3h),0.87(s,3h),0.77(s,3h),0.48(s,3h);hrms:calcdforc39h54o2n4br[m-oh]+689.33999,found689.34247.

2g:白色粉末,总收率32.3%,mp:97.6~101.7℃;1hnmr(400mhz,cdcl3):δ7.63~7.61(d,j=8.0hz,1h),7.33~7.11(m,2h),7.15~7.13(d,j=8.0hz,1h),5.70(s,2h),5.37~5.22(m,3h),3.22~3.18(dd,j=8.0,4.0hz,1h),2.83~2.79(dd,j=12.0,4.0hz,1h),2.02~1.94(dt,j=16.0,4.0hz,2h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.90(s,3h),0.89(s,3h),0.87(s,3h),0.77(s,3h),0.48(s,3h);hrms:calcdforc39h54o2n4br[m-oh]+689.33977,found689.34247.

2h:黄棕色粉末,总收率32.0%,mp:64.8~68.4℃;1hnmr(400mhz,cdcl3):δ8.22~8.20(d,j=8.0hz,1h),7.61~7.55(m,2h),6.89~6.87(d,j=8.0hz,1h),6.25(s,2h),5.37~5.22(m,3h),3.22~3.18(dd,j=8.0,4.0hz,1h),2.83~2.79(dd,j=12.0,4.0hz,1h),2.02~1.94(dt,j=16.0,4.0hz,2h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.90(s,3h),0.89(s,3h),0.87(s,3h),0.77(s,3h),0.48(s,3h);hrms:calcdforc39h54o4n5[m-oh]+656.41472,found656.41703.

2i:白色粉末,总收率35.2%,mp:81.6~84.2℃;13cnmr(100mhz,cdcl3)δ:176.43,162.45,142.79,133.89,132.26,131.47,129.51,122.10,117.39,112.92,78.46,55.60,55.23,54.65,47.03,46.34,45.24,41.13,40.77,38.75,38.22,37.91,36.47,33.26,32.54,32.17,31.64,31.42,30.15,29.19,28.86,27.58,27.11,26.65,25.31,23.09,22.86,22.45,22.19,17.81,16.27,15.09,14.84,13.63;hrms:calcdforc40h54o2n5[m-oh]+636.42720,found636.42509.

2j:白色粉末,总收率31.6%,mp:78.3~81.0℃;hrms:calcdforc39h55o2n4[m-oh]+611.42986,found611.43195.

2k:白色粉末,总收率33.2%,mp:74.0~75.5℃;1hnmr(400mhz,cdcl3):δ7.30~7.18(m,4h),7.23~7.21(m,2h),5.75(s,2h),5.33~5.33(m,3h),3.22~3.18(dd,j=8.0,4.0hz,1h),2.83~2.79(dd,j=12.0,4.0hz,1h),2.02~1.94(dt,j=16.0,4.0hz,2h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.90(s,3h),0.89(s,3h),0.87(s,3h),0.77(s,3h),0.48(s,3h);hr-ms:calcdforc40h57o2n4[m-oh]+625.44554,found625.44760.

3a:白色粉末,总收率30.3%,mp:174.8~177.4℃;1hnmr(400mhz,cdcl3):δ7.37~7.32(m,1h),7.08~7.04(dt,j=8.0,2.0hz,1h),7.01~6.99(d,j=8.0hz,1h),6.96~6.92(m,1h),5.70(s,2h),5.35~5.18(m,3h),,2.83~2.79(dd,j=12.0,4.0hz,1h),2.00~1.92(dt,j=16.0,4.0hz,1h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.89(s,3h),0.88(s,3h),0.87(s,3h),0.77(s,3h),0.63(s,3h);hrms:calcdforc39h56o3n4f[m+h]+647.43050,found647.43310.

3b:白色粉末,总收率28.9%,mp:156.4~158.2℃;1hnmr(400mhz,cdcl3):δ7.27~7.23(m,1h),7.09~7.04(t,j=8.0hz,2h),5.66(s,2h),5.30~5.18(m,3h),3.22~3.18(dd,j=8.0,4.0hz,1h),2.86~2.81(dd,j=12.0,4.0hz,1h),2.00~1.92(dt,j=16.0,4.0hz,1h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.89(s,3h),0.88(s,3h),0.87(s,3h),0.77(s,3h),0.63(s,3h);hrms:calcdforc39h56o3n4f[m+h]+647.43069,found647.43310.

3c:白色粉末,总收率31.8%,mp:159.4~162.7℃;1hnmr(400mhz,cdcl3):δ7.40~7.34(m,1h),7.24~7.22(d,j=8.0hz,1h),7.18~7.09(m,2h),5.76~5.67(m,2h),5.35~5.20(m,3h),3.22~3.18(dd,j=8.0,4.0hz,1h),2.83~2.79(dd,j=12.0,4.0hz,1h),2.02~1.94(dt,j=16.0,4.0hz,2h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.90(s,3h),0.89(s,3h),0.87(s,3h),0.77(s,3h),0.48(s,3h);

13cnmr(100mhz,cdcl3)δ:176.52,161.04,158.57,150.12,142.64,130.81,130.72,129.68,129.65,124.52,124.49,122.38,120.18,120.04,115.56,115.35,78.45,54.56,52.76,52.73,46.97,46.52,45.16,44.68,44.64,41.15,40.81,38.64,38.22,37.89,36.46,33.15,32.47,32.09,31.67,30.10,29.18,27.98,27.03,26.63,25.33,23.04,22.81,22.48,17.76,16.08,15.05,14.76;hrms:calcdforc39h56o3n4f[m+h]+647.43055,found647.43310.

3d:白色粉末,总收率30.1%,mp:167.5~169.5℃;1hnmr(400mhz,cdcl3):δ7.36~7.34(d,j=8.0hz,2h),7.20~7.17(d,j=12.0hz,2h),5.66(s,2h),5.27~5.25(t,j=4.0hz,1h),5.18(s,1h),3.22~3.18(dd,j=8.0,4.0hz,1h),2.83~2.79(dd,j=12.0,4.0hz,1h),2.02~1.94(dt,j=16.0,4.0hz,2h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.90(s,3h),0.89(s,3h),0.87(s,3h),0.77(s,3h),0.48(s,3h);hrms:calcdforc39h56o3n4cl[m+h]+663.40106,found663.40355.

3e:白色粉末,总收率29.3%,mp:165.5~168.2℃;1hnmr(400mhz,cdcl3):δ7.45~7.42(d,j=12.0hz,1h),7.35~7.25(m,2h),7.07~7.00(d,j=8.0hz,1h),5.77~5.76(d,j=4.0hz,2h),5.31~5.29(d,j=8.0hz,2h),5.26~5.23(m,1h),3.22~3.18(dd,j=8.0,4.0hz,1h),2.83~2.79(dd,j=12.0,4.0hz,1h),2.02~1.94(dt,j=16.0,4.0hz,2h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.90(s,3h),0.89(s,3h),0.87(s,3h),0.77(s,3h),0.48(s,3h);hrms:calcdforc39h56o3n4cl[m+h]+663.40059,found663.40355.

3f:白色粉末,总收率28.2%,mp:168.4~169.3℃;1hnmr(400mhz,cdcl3):δ7.51~7.49(d,j=8.0hz,1h),7.39(s,1h),7.25~7.23(d,j=8.0hz,1h),7.17~7.15(d,j=8.0hz,1h),5.67(s,2h),5.27~5.25(t,j=4.0hz,1h),5.17(s,1h),3.22~3.18(dd,j=8.0,4.0hz,1h),2.83~2.79(dd,j=12.0,4.0hz,1h),2.02~1.94(dt,j=16.0,4.0hz,2h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.90(s,3h),0.89(s,3h),0.87(s,3h),0.77(s,3h),0.48(s,3h);hrms:calcdforc39h54o2n4br[m-oh]+689.33972,found689.34247.

3g:白色粉末,总收率32.2%,mp:179.6~182.2℃;1hnmr(400mhz,cdcl3):δ7.63~7.61(d,j=8.0hz,1h),7.33~7.22(m,2h),6.93~6.92(d,j=8.0hz,1h),5.74(s,1h),5.35~5.24(m,3h),3.22~3.18(dd,j=8.0,4.0hz,1h),2.83~2.79(dd,j=12.0,4.0hz,1h),2.02~1.94(dt,j=16.0,4.0hz,2h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.90(s,3h),0.89(s,3h),0.87(s,3h),0.77(s,3h),0.48(s,3h);hrms:calcdforc39h56o3n4br[m+h]+707.35062,found707.35303.

3h:黄棕色粉末,总收率28.5%,mp:147.6~150.6℃;1hnmr(400mhz,cdcl3):δ8.26~7.24(d,j=8.0,1h),7.71~7.57(m,2h),6.98~6.96(d,j=8.0,1h),6.05~6.04(d,j=4.0,2h),5.37~5.36(d,j=4.0,2h),5.27~5.23(t,j=4.0hz,1h),3.22~3.18(dd,j=8.0,4.0hz,1h),2.83~2.79(dd,j=12.0,4.0hz,1h),2.02~1.94(dt,j=16.0,4.0hz,2h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.90(s,3h),0.89(s,3h),0.87(s,3h),0.77(s,3h),0.48(s,3h);13cnmr(100mhz,cdcl3)δ:176.41,150.85,146.65,142.48,134.11,129.99,129.47,128.79,125.37,122.42,78.45,54.65,53.04,48.43,46.94,46.48,45.08,41.11,40.74,38.62,38.21,37.88,36.45,33.08,32.43,32.06,31.60,30.06,29.18,27.57,27.02,26.62,25.28,23.01,22.79,22.39,17.73,16.15,15.05,14.77;hrms:calcdforc39h56o5n5[m+h]+674.42471,found674.42760。

3i:白色粉末,总收率31.4%,mp:96.6~98.0℃;hrms:calcdforc40h56o3n5[m+h]+654.43508,found654.43777.

3j:白色粉末,总收率30.7%,mp:143.4~145.2℃;1hnmr(400mhz,cdcl3):δ7.38~7.34(m,3h),7.24~7.18(m,2h),5.70(s,2h),5.27~5.25(t,j=4.0hz,1h),5.17(s,2h),3.22~3.18(dd,j=8.0,4.0hz,1h),2.83~2.79(dd,j=12.0,4.0hz,1h),2.02~1.94(dt,j=16.0,4.0hz,2h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.90(s,3h),0.89(s,3h),0.87(s,3h),0.77(s,3h),0.48(s,3h);

13cnmr(100mhz,cdcl3)δ:176.55,150.08,142.60,132.80,128.81,128.58,127.03,122.40,78.44,54.66,52.61,50.80,46.96,46.54,41.15,40.84,38.65,38.22,37.89,36.46,33.14,32.46,32.10,31.72,30.10,29.18,27.58,27.05,26.64,25.32,23.07,22.82,22.47,17.76,16.11,15.06,14.79;hrms:calcdforc39h57o3n4[m+h]+629.44020,found629.44252.

3k:白色粉末,总收率31.8%,mp:156.8~159.5℃;1hnmr(400mhz,cdcl3):δ7.29~7.15(m,3h),6.90~6.88(d,j=8.0hz,1h),5.68(s,1h),5.27~5.25(t,j=4.0hz,1h),5.17(s,2h),3.22~3.18(dd,j=8.0,4.0hz,1h),2.83~2.79(dd,j=12.0,4.0hz,1h),2.02~1.94(dt,j=16.0,4.0hz,2h),1.85~1.81(dd,j=8.8,3.2hz,2h),1.25(s,3h),1.10(s,3h),0.98(s,3h),0.90(s,3h),0.89(s,3h),0.87(s,3h),0.77(s,3h),0.48(s,3h);

13cnmr(100mhz,cdcl3)δ:176.48,150.38,142.58,135.75,130.97,130.66,128.67,127.28,126.22,122.38,78.45,54.65,52.76,49.10,46.96,46.49,45.14,40.82,38.22,37.89,36.46,33.13,32.47,27.58,27.04,26.63,25.32,23.06,22.82,22.45,22.19,18.74,17.75,16.11,15.06,14.79,13.63;hrms:calcdforc40h59o3n4[m+h]+643.45565,found643.45817.

药理实验

本研究工作采用mtt法,以顺铂(cisplatin)为阳性对照药,测定目标化合物对人胃癌细胞mkn-45、人乳腺癌细胞mcf-7和大鼠胶质瘤c6细胞的体外抗肿瘤活性,并测定了部分化合物的ic50。结果表明该化合物具有更优的抗肿瘤活性。

齐墩果酸及其衍生物对上述肿瘤细胞的体外抑制活性分析

将对数生长期的不同肿瘤细胞,用0.25%胰酶消化后,配制成一定浓度的单细胞悬液。根据细胞生长速度的差异,按4000个/孔接种于96孔板,每孔加入细胞悬液100μl。24h后,加入浓度为10μm的化合物和cisplatin及相应溶剂对照的完全培养基。每孔加100μl(dmso终浓度<0.1%),每组设3个平行孔,于37℃继续培养72h后,弃上清。每孔加入100μl含0.5mg/mlmtt的完全培养基,继续培养4h,弃上清后,每孔加入150μldmso溶解mtt甲瓒沉淀,微型振荡器振荡混匀后,酶标仪在参考波长450nm,检测波长570nm条件下测定光密度值(od),以溶剂对照处理的肿瘤细胞为对照组,用以下公式计算每种化合物作用下的,不同肿瘤细胞的存活率。

细胞抑制率(%)=(1-给药组平均od值/对照组平均od值)×100%

齐墩果酸及2c、3k对上述肿瘤细胞的半数抑制率的研究

将对数生长期的不同肿瘤细胞,用0.25%胰酶消化后,配制成一定浓度的单细胞悬液。根据细胞生长速度的差异,按4000个/孔接种于96孔板,每孔加入细胞悬液100μl。24h后,加入含不同浓度化合物及相应溶剂对照的完全培养基,每孔加100μl(dmso终浓度<0.1%),每种受试化合物设8个剂量组,每组设3个平行孔,于37℃继续培养72h后,弃上清。每孔加入100μl含0.5mg/mlmtt的完全培养基,继续培养4h,弃上清后,每孔加入150μldmso溶解mtt甲瓒沉淀,微型振荡器振荡混匀后,酶标仪在参考波长450nm,检测波长570nm条件下测定光密度值(od),以溶剂对照处理的肿瘤细胞为对照组,用以下公式计算化合物对肿瘤细胞的抑制率,并按中效方程计算ic50。

ic50=(对照组平均od值-给药组平均od值)/对照组平均od值×100%

体外抗肿瘤活性测试结果

部分化合物对上述三株肿瘤细胞的抑制率见表1。

表1目标物浓度为10μm时,对上述三株肿瘤细胞的抑制率数据

目标物2c、3h和oa对上述肿瘤细胞的ic50如表2所示。

表2目标物2c、3h和oa对上述肿瘤细胞的ic50数据

以上显示和描述了本发明的基本原理、主要特征和本发明的优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明精神和范围的前提下本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。

当前第1页1 2 
网友询问留言 已有0条留言
  • 还没有人留言评论。精彩留言会获得点赞!
1